As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Blue­bird re­port­ed that 17 peo­ple with sick­le cell dis­ease have start­ed the process of re­ceiv­ing its gene ther­a­py Lyf­ge­nia.

Blue­bird said in its

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.